SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients
January 09, 2023 08:25 ET
|
SeaStar Medical Holding Corporation
Building upon demonstrated clinical success, the pivotal study will evaluate the Selective Cytopheretic Device in adults with AKI requiring CKRT DENVER, Jan. 09, 2023 (GLOBE NEWSWIRE) --...
SeaStar Medical’s Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement for Pediatric Acute Kidney Injury in First Pediatric Acute Disease Quality Initiative (ADQI) Meeting
November 07, 2022 12:30 ET
|
SeaStar Medical Holding Corporation
– The SCD is currently being evaluated by the FDA for a Humanitarian Device Exemption (HDE) marketing approval for use in children (> 20 kgs) with AKI – The Company expects the FDA to complete...
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials
August 05, 2022 07:30 ET
|
Arch Biopartners
TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with...
Terumo Blood and Cell Technologies collaborates with Eliaz Therapeutics in the development and commercialization of a novel therapeutic apheresis treatment for acute kidney injury (AKI)
July 27, 2022 17:22 ET
|
Terumo Blood and Cell Technologies
LAKEWOOD, Colo., U.S., and SANTA ROSA, Calif., U.S., July 27, 2022 (GLOBE NEWSWIRE) -- Acute kidney injury (AKI) and sepsis-induced acute kidney injury (S-AKI) are life-threatening conditions, with...
Acute Kidney Injury Pipeline to Progress with Novel and Emerging Drugs for Treatment, Analyzes DelveInsight
April 13, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 13, 2022 (GLOBE NEWSWIRE) -- Acute Kidney Injury Pipeline to Progress with Novel and Emerging Drugs for Treatment, Analyzes DelveInsight Acute Kidney Injury takes place if the...
Renibus Therapeutics Strengthens IP Position with Additional US Patent
April 13, 2022 08:00 ET
|
Rénibus Therapeutics Inc.
SOUTHLAKE, Texas, April 13, 2022 (GLOBE NEWSWIRE) -- Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today...
Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A Funding
February 15, 2022 09:00 ET
|
Rénibus Therapeutics Inc.
Founder, CEO and healthcare venture capitalist, Stonebanks brings 25 years of experience to Renibus leadership team Renibus closes $35 million Series A; Funds will be used to advance the development...
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 12, 2021 07:00 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2021
October 28, 2021 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present abstracts at the American Society of...
Angion to Participate in Upcoming September Investment Conferences
September 02, 2021 00:20 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...